SOHO 2024 | Dr. Astrid Pavlovsk Discusses the Current Status and Prospects of the Diagnosis and Treatment of Aggressive Lymphomas

SOHO 2024 | Dr. Astrid Pavlovsk Discusses the Current Status and Prospects of the Diagnosis and Treatment of Aggressive Lymphomas

Aggressive lymphomas progress rapidly and are prone to relapse, with existing treatments still failing to achieve a satisfactory cure rate. Particularly for high-risk patient groups, the demand for precise and efficient treatments is more urgent. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) was held in Houston, USA, from September 4th to 7th, 2024, attracting top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new strategies for treatment. During the conference, "Hematology Frontier" had the honor to interview Dr. Astrid Pavlovsk from the Pavlovsky Center. She provided an in-depth analysis of the efficacy, safety, and current status of new therapies in the treatment of aggressive lymphomas, with a special focus on key issues such as patient individual differences, offering insights for clinical practice.
EHA Expert Interview | Professor Hongyan Tong: New MDS Classification and Advances in the MDS-f Subtype

EHA Expert Interview | Professor Hongyan Tong: New MDS Classification and Advances in the MDS-f Subtype

The 29th European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain, from June 13-16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, the latest classification standards and clinical research outcomes for MDS received widespread attention. "Oncology Frontier - Hematology Frontier" invited Professor Hongyan Tong from The First Affiliated Hospital, Zhejiang University School of Medicine to provide an in-depth interpretation of the key updates in the latest WHO MDS classification standards and share her team's groundbreaking research achievements in MDS, particularly in the MDS-f subtype.
Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

On July 2, 2024, the "ADC High-Level Closed-Door Seminar," chaired by Vice President Yong Yang of China Pharmaceutical University and President Jin Li of Shanghai Gaobo Oncology Hospital, was grandly held in Shanghai. The seminar explored the current status and future of ADC development. During the event, Oncology Frontier interviewed Professor Baohui Han from the Shanghai Chest Hospital . Combining recent ASCO conference updates, Professor Han analyzed the efficacy results and safety management points of ADC treatment in NSCLC and shared insights on the future prospects of ADC development.
EHA China’s Voice丨A New Perspective on Immune Escape in AML: Dr. Yang Liang’s Team Unveils the Regulatory Mechanism of FLT3-ITD

EHA China’s Voice丨A New Perspective on Immune Escape in AML: Dr. Yang Liang’s Team Unveils the Regulatory Mechanism of FLT3-ITD

The 29th Annual Congress of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from all over the world every year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, a study by Dr. Yang Liang from Sun Yat-sen University Cancer Center was selected for poster presentation, exploring how FLT3-ITD promotes immune escape in AML cells by up-regulating CD47 expression and reducing the phagocytic ability of macrophages. To provide insight into these research findings, "Oncology Frontier-Hematology Frontier" invited Dr. Yang Liang to give us a brief introduction to the study.
Professor Qian Jiang: Exploring New Models of Regional Academic Exchange, Beijing Hematology Academic Annual Meeting Concludes Successfully

Professor Qian Jiang: Exploring New Models of Regional Academic Exchange, Beijing Hematology Academic Annual Meeting Concludes Successfully

On July 5th, the 17th Beijing Hematology Academic Annual Meeting, hosted by the Beijing Medical Association Hematology Branch, concluded successfully in Beijing. This year's meeting featured innovative and unique formats and rich content, providing a platform for participants to share cutting-edge advancements and experiences. It also showcased the original research achievements in the field of hematology in Beijing. "Oncology Frontier - Hematology Frontier" invited Professor Qian Jiang, the current chair of the Beijing Medical Association Hematology Branch, the main organizer of this conference, and a professor at Peking University People's Hospital, to share the highlights and unique aspects of the meeting and to discuss its far-reaching impacts on the future.
Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation

Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation

At the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference, the research team led by Dr. Xiaoyu Zhu and Dr. Aijie Huang from The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) garnered significant attention. Their study on the efficacy and safety of avatrombopag for treating thrombocytopenia following cord blood transplantation (UCBT) was selected for oral presentation (OC33.3), with Dr. Huang delivering the report. This study not only showcases the exceptional capabilities of Chinese research teams in hematology but also contributes valuable insights to the global hematology community. "Oncology Frontier - Hematology Frontier" had an exclusive interview with Dr. Aijie Huang to delve deeper into the research and discuss future plans in the field of UCBT.
Dr. Baohui Han Analyzes the Relationship Between PD-L1 Expression and Crizotinib Efficacy in ROS-1 Fusion-Positive NSCLC

Dr. Baohui Han Analyzes the Relationship Between PD-L1 Expression and Crizotinib Efficacy in ROS-1 Fusion-Positive NSCLC

The development of modern oncology has provided a variety of groundbreaking treatment options for lung cancer, making it one of the most rapidly evolving solid tumors. To help clinical physicians gain an in-depth and comprehensive understanding of the significant advancements in this field, "Oncology Frontier" has joined forces with Dr. Hua Zhong and Dr. Baohui Han, Director of the Department of Respiratory and Critical Care Medicine at Shanghai Jiao Tong University School of Medicine Affiliated Chest Hospital,  to create a clinical progress series called "Zhong's Insights, Hui's Wisdom." By interpreting high-quality clinical studies in the field of lung cancer, this series aims to promote the improvement of clinical diagnostic and treatment practices. In this 23rd issue of the “Zhong's Insights, Hui's Wisdom” series, Dr. Hua Zhong and Dr. Baohui Han provide their expert analysis on the relationship between PD-L1 expression levels and the efficacy of first-line crizotinib treatment in ROS-1 fusion-positive non-small cell lung cancer (NSCLC) patients. The study was published in Lung Cancer by the Department of Respiratory and Critical Care Medicine at Shanghai Jiao Tong University School of Medicine Affiliated Chest Hospital, with Dr. Runbo Zhong as the corresponding author.
Eur Urol | Biomarkers in Prostate Cancer Screening: Sometimes, “More Is Better”

Eur Urol | Biomarkers in Prostate Cancer Screening: Sometimes, “More Is Better”

Prostate cancer is one of the most common malignancies in men, and the widespread use of prostate-specific antigen (PSA) testing has significantly improved early diagnosis rates. However, a series of prostate cancer screening trials in Europe have found that PSA-based screening benefits only a subset of patients. How can more prostate cancer patients benefit from screening? Are there other biomarkers that can be used for screening? A recent article published in European Urology discusses these questions. We have summarized the key points for our readers.